Pneumococcal conjugate second or third-dose vaccines (PCVc) in Lithuania
Lithuania: Pneumococcal conjugate second or third-dose vaccines (PCVc) was 87.0% in 2025. ◆ Volatile
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Lithuania, 2008–2025
Source: World Health Organization, Global Health Observatory.
Analysis
The most recent figure for pneumococcal conjugate second or third-dose vaccines (pcvc) in Lithuania is 87.0%, measured in 2025. That is the highest value across all 18 years on record.
The figure is up 4.8% over five years.
Over the whole period, pneumococcal conjugate second or third-dose vaccines (pcvc) in Lithuania peaked at 87.0% in 2024 and was at its lowest, 0.0%, in 2008.
That places Lithuania 86th out of 194 countries with data for 2025, putting it in the middle of the range.
The series is highly variable year to year, so single readings are best treated with caution.
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Lithuania, year by year
| Year | Value | Change |
|---|---|---|
| 2008 | 0.0% | — |
| 2009 | 0.0% | — |
| 2010 | 0.0% | — |
| 2011 | 0.0% | — |
| 2012 | 0.0% | — |
| 2013 | 0.0% | — |
| 2014 | 0.0% | — |
| 2015 | 0.0% | — |
| 2016 | 82.0% | — |
| 2017 | 83.0% | +1.2% |
| 2018 | 82.0% | -1.2% |
| 2019 | 82.0% | +0.0% |
| 2020 | 83.0% | +1.2% |
| 2021 | 82.0% | -1.2% |
| 2022 | 81.0% | -1.2% |
| 2023 | 82.0% | +1.2% |
| 2024 | 87.0% | +6.1% |
| 2025 | 87.0% | +0.0% |
Lithuania compared with similar countries
- Lithuania's 87.0% is below the median for high income countries, which is 91.0%, 96% of the median. (63 countries reporting)
- Lithuania's 87.0% is above the median for Europe & Central Asia, which is 87.0%, 1.0× the median. (51 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | 2 |
| 2010s | 32.9% | 0.0% | 83.0% | 10 |
| 2020s | 83.7% | 81.0% | 87.0% | 6 |
Countries ranked near Lithuania
- 86 Kenya 87.0% compare
- 86 Kiribati 87.0% compare
- 86 Dominican Republic 87.0% compare
- 86 Netherlands 87.0% compare
- 86 Niger 87.0% compare
More health data for Lithuania
- Un projection of annual infant deaths, annual growth rate 0 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate -0.4537 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,909 deaths per 1,000 people (2090)
- Number of infants who die before age 1 5 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2025)
- Population ages 00-04, female, annual growth rate -4.51 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0199 units per person (2025)
- Population ages 00-04, male, annual growth rate -4.59 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is pneumococcal conjugate second or third-dose vaccines (pcvc) in Lithuania?
- Pneumococcal conjugate second or third-dose vaccines (pcvc) in Lithuania was 87.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Lithuania?
- The highest recorded value was 87.0% in 2024.
- What is the lowest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Lithuania?
- The lowest recorded value was 0.0% in 2008.
- How does Lithuania rank for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Lithuania ranks 86th out of 194 countries with data for 2025.
- Where does this Lithuania data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 18 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).